ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Entresto Study Misses Primary Endpoint americanpharmaceuticalreview
August 02, 2019Novartis announced topline results from the global Phase III PARAGON-HF study, investigating the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients.
Pharma Sources Insight January 2025
